Dr Reddy's Laboratories has launched Eszopiclone tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market on Apr. 15, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The Lunesta (eszopiclone) tablets C-IV brand and generic combined had U.S. sales of approximately USD 887 million MAT for the most recent twelve months ending in Jan'14 according to IMS Health.

Shares of the company declined Rs 21.7, or 0.84%, to trade at Rs 2,555.75. The total volume of shares traded was 3,614 at the BSE (10.40 a.m., Wednesday).